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Abstract
Background: The mucosae of the oral cavity are different at the histological level but appear all equally exposed
to common genotoxic agents. As a result of this exposure, changes in the mucosal epithelia may develop giving
rise to Oral Potentially Malignant Lesions (OPMLs), which with time may in turn progress to Oral Squamous Cell
Carcinomas (OSCCs). Therefore, much effort should be devoted to identify features able to predict the likeliness of
progression associated with an OPML. Such features may be helpful in assisting the clinician to establish both
appropriate therapies and follow-up schedules. Here, we report a pilot study that compared the occurrence of
DNA aneuploidy and chromosomal copy number aberrations (CNAs) in the OPMLs from different oral anatomical
subsites.
Methods: Samples from histologically diagnosed OPMLs were processed for high resolution DNA flow cytometry
(hr DNA-FCM) in order to determine the relative DNA content expressed by the DNA index (DI). Additionally, array-
Comparative Genomic Hybridization (a-CGH) analysis was performed on DNA obtained from diploid nuclei
suspensions directly. When aneuploid nuclei were detected, these were physically separated from diploid nuclei on
the base of their DI values by means of a DNA-FCM-Sorter in order to improve the a-CGH analysis.
Results: Tongue OPMLs were more frequently associated with DNA aneuploidy and CNAs than OPMLs arising
from all the other mucosal subsites.
Conclusions: We suggest that the follow-up and the management of the patients with tongue OPMLs should
receive a distinctive special attention. Clearly, this hypothesis should be validated in a prospective clinical study.
Background
Oral mucosae are exposed to genotoxic insults princi-
pally from chemical components contained in cigarette
smoke, tobacco, food and beverages. About two thirds
of oral squamous cell carcinomas (OSCCs) may be
explained by tobacco cigarette and alcohol consumption
[1]. In particular, tobacco smoke and alcohol appear to
synergistically influence the development of oral epithe-
lial dysplasia [2]. The role of other agents such as fungi
and viruses is also recognized including the sexually
transmitted human papilloma virus (HPV). This virus,
in particular, appears to be linked to a recent surge of
cancers especially in young individuals and in anatomi-
cal subsites located at the back of the oral cavity as well
as in the pharynx [3,4]. As a result of these genotoxic
insults, the normal epithelia may undergo with time to
morphological changes leading to lesions appearing as
patches/plaques with white (leukoplakia) or red (ery-
throplakia) or mixed color (erythroleukoplakia) [5].
Altogether, these lesions are referred to as Oral Poten-
tially Malignant Lesions (OPMLs). The actual transfor-
mation rate associated with these lesions is quite
different, being those with a mixed appearance at a
higher risk of neoplastic progression [6]. These lesions
may or may not be dysplastic. Both macroscopic and
microscopic features may be evaluated differently due to
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the subjective criteria of classification. It is widely
accepted that OPMLs associated with dysplasia deserve
a closer clinical follow-up and earlier surgical treatment
on the basis of a higher potential of malignant transfor-
mation with respect to non dysplastic OPMLs [7].
Concerning the anatomical subsites of development of
OPMLs, it should be considered that the stratified
epithelia covering the structures present in the oral cav-
ity have diverse histological features, which may result
in different levels of permeability. In addition, different
oral subsites with the same pattern of epithelial differen-
tiation were found to display different permeability
properties [8]. A different exposure to genotoxic insults
may also occur at particular regions due to other causes
i.e., due to a pooling effect. Both different permeability
and different exposure may be reflected at the patho-
physiological level by different rates of occurrence of
OPMLs and progression of these lesions to malignant
transformation among different subsites.
Most OSCCs arise from the floor of the mouth, the
soft palate complex and the lateral/ventral tongue [9,10].
Concerning the tongue, oncologically relevant lesions
involve almost exclusively its lateral and ventral subsites,
sparing the dorsum. It has also been reported that the
lateral tongue displays a high recurrence rate after sur-
gery for OSCC [11]. Interestingly, however, a large study
showed that there was no survival difference between
patients with tongue cancer and cancers located at other
oral cavity anatomical subsites [12].
It is conceivable that the epithelia covering subsites at
high risk of cancerization [13] are more frequently asso-
ciated with dysplasia. Alternatively, dysplastic lesions at
these subsites may have a higher propensity to undergo
malignant transformation.
Whatever hypothesis is true, it is expected that large
genomic changes such as DNA aneuploidy, should be
found more frequently associated with OPMLs arising
from subsites at high risk of cancerization than in low
risk subsites. Along this line, an early report indicated
that DNA aneuploidy proved to be a prognostic indica-
tor of malignancy progression in oral cancer [14].
Recently, it has also been proposed that DNA ploidy
analysis helps to identify oral epithelial dysplasia with a
high risk of malignant progression [15]. Furthermore, a
pilot study reported that dysplasia from high risk sub-
sites have a greater tendency to include genetic aberra-
tions such as loss of heterozygosity (LOH) on 3p and/or
9p associated with elevated risk of progression [16].
In the present study, we took advantage of high reso-
lution DNA flow cytometry (hr DNA-FCM) to detect
subclones with DNA aneuploidy. Additionally, we evalu-
ated by a-CGH chromosomal segmental gains and losses
and chromosomal numerical aberrations, which are gen-
erally defined as DNA copy number aberrations (CNAs).
This last approach was done, for the DNA aneuploid
lesions, after the sorting DNA aneuploid epithelial
nuclei. Using these techniques, we aimed to explore the




Patients with OPMLs were recruited in two different
medical centers: the Oral Medicine and Oral Oncology
Section of the University of Turin at the A.S.O. S. Luigi
Gonzaga (Orbassano-Turin) and at the Department of
Otolaryngology, “S. Martino Hospital” in Genoa. Patient
written consent was obtained in every case according to
the Institutional Ethic Committees (A.S.O. S. Luigi Gon-
zaga Prot. N. 11780 and S. Martino Hospital Prot. N.
1084) during an interview in which their tobacco and
alcohol habits were recorded.
Inclusion criteria were the presence of one or more
OPMLs (homogeneous and non-homogeneous leukopla-
kias, erythroplakias and erythroleukoplakias) affecting
only a single oral cavity subsite and not extending to
other subsites. The patients were all at first presentation,
with no history of a previous cancer of the oral cavity.
For each individual OPML, micro-biopsies (by means
of a curette) and incisional biopsies were obtained as
previously detailed [17]. In performing the micro-biop-
sies, care was taken to cause slight bleeding to ensure
that the basal layers of the epithelium had been col-
lected [17]. The samples from the OPMLs, when these
were relatively large, included also the lesion margins.
Micro-biopsies were also obtained from “oral distant
fields” (ODFs) at a distance from co-existing OPMLs
and characterized by visually normal appearing mucosa.
Both micro-biopsies and incisional biopsies were sub-
divided in order to serve for both FCM and a-CGH ana-
lyses and histological diagnosis. The samples for DNA-
FCM and a-CGH were either immediately submitted to
FCM analysis or stored at -20°C to be processed at a
later time. The histological diagnosis of dysplasia in
ODFs and OPMLs was carried out by a specially trained
pathologist, according to the WHO guidelines [17,18].
ODF samples never harbored dysplasia. Dysplastic
lesions included all grades of dysplasia.
Specific data concerning lesion size and homogeneity
could not be reliably retrieved from the patients’ clinical
files.
Table 1 reports the number of patients enrolled in the
study and the type and number of tissue samples used
to perform FCM and a-CGH analyses. Some patients
presented multiple lesions in the same anatomical sub-
site. Patients with tissue samples derived from the ton-
gue or from all the other subsites were referred to as T
or O patients respectively.
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Processing of tissue samples for high resolution DNA flow
cytometry (hr DNA-FCM) analysis and sorting
Tissue samples were processed to obtain DAPI stained
nuclei suspensions following the method of Otto et al.
[19] with modifications. High resolution DNA flow cyto-
metry (hr DNA-FCM) of these samples was used as pre-
viously described in details[20] to obtain DNA content
histograms and to evaluate the DNA Index (DI). DNA
diploid controls were represented by gender-specific
human lymphocytes. The mean CV of the correspond-
ing DNA diploid GO-G1 peaks was 1.2 ± 0.2%. The
DNA diploid (DI = 1) and aneuploid sublines (DI≠1)
detected in ODFs and OPMLs were sorted using a
Cyflow Space FCM equipped with a PPCS unit (Partec
GmbH, Muenster, Germany) at the purity of about 99%.
Patients with tissue samples derived from the tongue or
from all the other subsites were referred as T patients
or O patients respectively. DI values were determined in
21 T and 86 O patients (Table 2).
The DNA aneuploid sublines detected by hr-DNA
FCM were physically separated from the DNA diploid
components with a FCM-sorter and submitted, as a
pure subpopulation of nuclei from epithelial cells, to a-
CGH to provide a genome-wide measurement of DNA
copy number aberrations (CNAs).
Concerning DNA diploid lesions, no enrichment for
epithelial cell nuclei was performed. Therefore, diploid
nuclei from non-epithelial cells may be present in the
sample processed for a-CGH.
After DNA FCM analyses and before DNA extraction,
both aneuploid and diploid nuclei were washed twice
with H2O at 3000 rpm, for 15 minutes at 10°C.
High resolution a-CGH analysis
The measurements of CNAs were performed on 6 DNA
aneuploid and 29 DNA diploid samples from 27 patients
(8 T and 19 O patients, respectively) using the high
resolution oligonucleotide Human Genome CGH 105 K
array platform (Agilent Technologies, Santa Clara, CA).
DNA was extracted using ArchivePure DNA kit (5-
Prime Hamburg, Germany) with some modifications:
after proteins precipitation the DNA was purified by
phenol-chloroform extraction and collected by ethanol
precipitation adding 20 μg of glycogen (20 mg/ml) as
carrier. DNA quality and quantity were assessed by
agarose gel and ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE). A pool of normal male or
female DNA (Promega, Madison, WI) was used as refer-
ence DNA. A quantity of 50 ng of genomic DNAs (test
and reference) was amplified by GenomePlex Whole
Genome Amplification Kit (Sigma-Aldrich, St. Louis,
MO) that allows to generate a representative amplifica-
tion of genomic DNA. The kit uses a linker mediated
primer PCR amplification technology based upon ran-
dom fragmentation of genomic DNA and conversion of
the resulting small fragments to PCR-amplifiable Omni-
Plex Library molecules flanked by universal priming
sites. The OmniPlex library is then PCR amplified using
Table 1 Patients enrolled in the study, type and number









§Fifty-six males and 51 females, with a median age of 58 years, range 26-86
without actual or previous oropharyngeal cancer. Sixty-four patients showed
presence of lesions on the buccal mucosa, 21 on the tongue, 8 on the gum
and 14 on other subsites.
*These 13 male and 14 female patients, with a median age of 64, range 26-
83, were a subgroup of the 107 patients examined by FCM analysis. Fourteen
patients showed presence of lesions on the buccal mucosa, 8 on the tongue,
3 on the gum and 2 on other subsites.
Table 2 Distribution of patients with OPMLs+ODFs in the tongue (T patients) or in all the other oral mucosal regions
(O patients) or in Buccal Mucosa (BM patients) with respect to DNA diploid or aneuploid status
OPMLs+ODFs
O patients vs. T patients (OR = 6.1; p = 0.0008)*
T patients vs. BM patients (OR = 7.0; p = 0.001)§
O patients T patients BM patients
DNA diploid 68 8 52
DNA aneuploid 18 (21%) 13 (62%) 12 (10%)
Total 86 21 64
*Once stratified for presence/absence of dysplasia in the OPMLs, ORM-H = 5.5 (p = 0.002).
§Once stratified for presence/absence of dysplasia in the OPMLs, ORM-H = 5.9 (p = 0.001).
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universal oligonucleotide primers. After purification of
PCR products by GenElute PCR Clean-Up Kit (Sigma-
Aldrich), amplified DNA was quantified using the ND-
1000 Spectrophotometer (Thermo Scientific). For each
array, 2 μg amplified test and reference DNAs were
labeled by Bioprime Labeling Kit (Invitrogen, Paisley,
UK) following the manufacture’s protocol. Unincorpo-
rated nucleotides were removed on Microcon YM-30 fil-
ters (Millipore, Billerica, MA) according to the
manufacturer’s protocol. Labeled DNA quality analysis
and quantization were performed by NanoDrop ND-
1000 Spectrophotometer and parameters that predicted
successful hybridization were a specific activity of 25 to
40 and 20 to 35 for cyanine-3 and cyanine-5 labeled
sample, respectively. Prior to the denaturation step at
95°C for 3 min, 50 μg Cot-1 DNA (Invitrogen) and con-
trol targets (Agilent Technologies) were added to cya-
nine 5- and cyanine 3-labeled DNA mixture.
Hybridization mix was incubated at 37°C for 30 min,
and applied to array. Hybridization was carried out for
40 hr at 65°C in a rotating hybridization oven (Agilent
Technologies) at 20 rpm. After washes according to the
manufacture’s recommendations, spot fluorescence was
measured by the Agilent G2565BA Scanner and images
were processed by Feature Extraction software (version
9.5.3.1) (Agilent Technologies). Data files were analyzed
by Agilent CGH Analytics Software (version 3.5.14)
according to ADM-2 algorithm. The quality of each
experiment was assessed by QC metric tool. Raw data
were uploaded in Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28868)
Relationship between DNA copy number aberrations
(CNAs) and oral mucosa subsites
In order to investigate the link between CNAs and oral
subsites, we first performed a contrast match with
respect to sample DNA aneuploidy and with respect to
smoke habit and gender of the patients. Overall, we
obtained 37 different tissue samples from 27 patients (8
T patients and 19 O patients respectively) already
assayed by hr DNA-FCM analysis (Table 1). Subse-
quently, the incidence of CNAs occurring in the samples
of the two groups of patients was determined.
The sum of the segmental and numerical aberrations,
which occurred within 41 chromosomal arms (no a-
CGH probes were available for p arms of chromosomes
13, 14, 15, 21 and 22), irrespective of the size of the
genomic region involved, were referred to as total gain,
total loss and total gain+loss of genomic DNA. The sum
was obtained by assigning a value of 1 for each chromo-
somal arm showing one or more CNAs events. In this
way, each patient/lesion was characterized by a score
ranging from 0 (no event detected) to 41 (gain/loss/gain
+loss events detected in every arm of the chromosomes
for which a-CGH probes are available). The rationale
that prompted us to adopt this approach is that the
pathophysiological consequences, in terms of genetic
instability and risk of cancer development for the oral
mucosa, of either large or small chromosomal aberra-
tions are not fully established.
When multiple tissue samples were available from a
single oral lesion, the highest sum value per chromoso-
mal arm was assigned. By using this approach, we
obtained for each patient/lesion a single aberration
value.
Results
Tongue OPMLs have a higher occurrence of DNA
aneuploidy with respect to non-tongue OPMLs
In order to evaluate the relationship between DNA
aneuploidy and oral mucosa subsites, the patients were
subdivided between those having tissue samples from
tongue (T patients, n = 21), those having tissue sam-
ples from all the other sites (O patients, n = 86) and
those having tissue samples from Buccal mucosa (BM
patients, n = 64). These latter group, which was the
most represented subsite, was used to address whether
the Tongue patients’ lesions were different in terms of
DNA aneuplody with respect to the lesions arising in a
different specific oral mucosa subsite. The incidence of
DNA aneuploidy occurring in the samples of the three
groups of patients was determined. When both DNA
aneuploid and DNA diploid sublines were detected in
the same tissue sample, we took as representative the
aneuploid one. Table 2 shows that DNA aneuploidy
was more frequent among T patients with respect
to both O patients (p = 0.0008) and BM patients (p =
0.001).
To verify whether the presence of ODFs in addition to
the OPMLs could affect the results, we performed two
separate analyses on OPMLs (Table 3) and on ODFs
(Table 4), which confirmed that DNA aneuploidy was
significantly more frequent among T patients with
respect to both O patients and BM patients.
Figure 1 shows the frequency of DNA aneuploidy
among ODFs, non-dysplastic OPMLs and dysplastic
OPMLs subdivided in either the tongue or all the other
anatomic subsites.
Tongue OPMLs have a higher occurrence of CNAs with
respect to OPMLs in all the other mucosa anatomical
sites
We tested the hypothesis that the frequencies of CNAs
in OPMLs of T patients and O patients were different.
As detailed in Materials and Methods, we used a score
related to CNA gains and losses. A subset of 27 patients
(8 T patients and 19 O patients, respectively) were
analyzed.
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Figure 2A shows that the total gain, including both
segmental and numerical aberrations (see Materials and
Methods), was higher in the tongue OPMLs than in the
OPMLs from all the other subsites (p = 0.032 ANOVA
F-test; p = 0.085 Mann-Whitney test). A similar result
was obtained when only segmental chromosomal aberra-
tions were analyzed (p = 0.072 ANOVA F-test; p = 0.07
Mann-Whitney test; data not shown). Figure 2B shows
Table 3 Distribution of patients with OPMLs in the tongue (T patients) or in all the other oral mucosal subsites





O patients vs. T patients (OR = 5.2; p = 0.003)*
T patients vs. BM patients (OR = 5.9; p = 0.002)§
O patients T patients BM patients
DNA diploid 71 10 54
DNA aneuploid 15 (17%) 11 (52%) 10 (16%)
Total 86 21 64
Non-dysplastic OPMLs
O patients vs. T patients (OR = 3.6; p = 0.07)
T patients vs. BM patients (OR = 3.6; p = 0.069)
O patients T patients BM patients
DNA diploid 65 9 48
DNA aneuploid 12 (16%) 6 (40%) 9 (16%)
Total 77 15 57
Dysplastic OPMLs
O patients vs. T patients (OR = 10; p = 0.12)
T patients vs. BM patients (OR = 36; p = 0.029)
O patients T patients BM patients
DNA diploid 6 1 6
DNA aneuploid 3 (33%) 5 (83%) 1 (14%)
Total 9 6 7
*Once stratified for presence/absence of dysplasia in the corresponding OPMLs, ORM-H = 4.5 (p = 0.005).
§ Once stratified for presence/absence of dysplasia in the corresponding OPMLs, ORM-H = 5.2 (p = 0.003).
Table 4 Distribution of “oral distant fields” (ODFs) collected from patients with OPMLs in the tongue (T patients) or in
all the other oral mucosal regions (O patients) or in Buccal Mucosa (BM patients) with respect to DNA diploid or
aneuploid status
ODFs
O patients vs. T patients (OR = 11; p = 0.005)*
T patients vs. BM patients (OR = 10; p = 0.007)§




DNA aneuploid 3 (5%) 5 (38%) 3 (6%)
Total 56 13 51
*Once stratified for presence/absence of dysplasia in the corresponding OPMLs, ORM-H = 14 (p = 0.003).
§Once stratified for presence/absence of dysplasia in the corresponding OPMLs, ORM-H = 13 (p = 0.004).
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the total gains (including both segmental and numeri-
cal aberrations) for tongue and non-tongue OPMLs
after subdividing them according to DNA ploidy. Ton-
gue DNA aneuploid OPMLs were characterized by a
higher total gains than non-tongue DNA aneuploid
OPMLs (p = 0.002 ANOVA F-test; p = 0.033 Mann-
Whitney test). A statistically significant difference was
also found when only segmental chromosomal aberra-
tions were considered for the analysis (p = 0.001
ANOVA F-test; p = 0.028 Mann-Whitney test; data
not shown). Stratification for histology grade, smoking
habit or gender, maintained the observed relationship
between the CNAs total gains and anatomical subsite
(data not shown).
The same analyses were performed considering the
total losses or the combined gains plus losses providing
no statistically significant differences (data not shown).
Concerning the chromosomal arms showing statistical
significant segmental gains (p < 0.05) in the Tongue
OPMLs with respect to all the other oral mucosa sites,
we found the 7p e 20q (present in 5 out of 8 Tongue
samples), 1p, 16p e 16q (present in 4 out of 8 Tongue
samples).
Discussion
Over the last decade, oral cancer prognosis remained
quite dismal if compared with the improvement
achieved for cancers arising in other anatomical dis-
tricts. Despite existing recommendations for early detec-
tion, this failure was most likely due to the fact that the
diagnosis of oral cancer was performed at advanced
stages of the disease. Therefore, a prompt recognition of
OPMLs with a high potential of cancer development
and the early detection of OSCC appear essential to
improve patients’ outcomes.
This pilot study clearly indicated that tongue OPMLs
(mainly leukoplakias) were associated with a high
Figure 1 Percentage of DNA aneuploid tissue samples, as
determined by high resolution DNA flow cytometry (hr DNA-
FCM), found in the tongue and in all the other anatomical oral
mucosa subsites for Oral Distant Fields (ODFs), non-dysplastic
and dysplastic Oral Potentially Malignant Lesions (nd-OPMLs
and d-OPMLs, respectively). OR, odd ratio. The numerical data are
shown in Tables 3 and 4. Standard errors for each data point are
shown as vertical bars. Figure 2 Total gains of CNAs (see Material and Methods for
details) of the tongue Oral Potentially Malignant Lesions
(OPMLs) or of OPMLs from all the other anatomical mucosa
subsites. The values ranged from 0 (no DNA copy gains) to 41 (one
or more gains found in each one of the investigated chromosomal
arms). (A) Unstratified data. (B) Data stratified for DNA aneuploidy.
The number of samples in each group is shown. Each box
represented the median and the first and third quartiles, and the
whiskers extended as far as the minimum and maximum values
after exclusion of the outliers (values more than 1.5 interquartile
ranges below the lower quartile or above the upper quartile).
Excluded outliers (with value less than 3 interquartile ranges outside
the first and third quartiles) were displayed as circles.
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frequency of DNA aneuploidy and CNAs with respect to
OPMLs in all the other mucosa subsites. In particular,
this finding held also when we compared tongue and
buccal mucosa, which was the most frequently affected
subsite in the present series.
The preferential development of dysplasia and DNA
aneuploidy in the tongue OPMLs may suggest to the
clinician to adopt a shorter time interval in the follow-
up. An early large study on oral premalignant lesions
indicated that, in addition to OPMLs in the floor of the
mouth and in the lips, tongue leukoplakias were at a
higher risk being more frequently associated with dys-
plasia and carcinoma [13]. Furthermore, in optimal
agreement with our data, a recent pilot study demon-
strated, by using image cytometry, that OPMLs originat-
ing from the tongue displayed a higher frequency of
DNA aneuploidy than OPMLs from all the other anato-
mical subsites [21].
Remarkably, we also found that the frequency of DNA
aneuploidy in the tongue ODFs with respect to the
ODFs from all the other oral subsites was much higher.
This may partially result from the fact that on average
the distance between the tongue ODFs and the corre-
sponding OPMLs was smaller with respect to the dis-
tance between the ODFs and OPMLs in all the other
oral subsites.
Our results appear in good agreement with previously
published DNA ploidy studies [13,20-22]. In addition,
we added here clear evidence that tongue OPMLs dis-
played a higher occurrence of gain-related CNAs. This
finding was clearly evident with the use of a composite
biomarker (total gain of CNAs), which was simply the
sum of numbers of gains from every single chromo-
some. We suggest that this new biomarker may be use-
ful to assess the potential transformation risk associated
to OPMLs. It may be also worth to further investigate
whether specific chromosomal aberrations associated
with tongue OPMLs (for example, the segmental gains
in 7p, 20q, 1p, 16p and 16q) may contain gene loci with
oncogenic potential.
Altogether, our data indicate that the detection of his-
tological dysplasia, DNA aneuploidy and chromosomal
aberrations in the tongue OPMLs might be associated
with a higher risk of cancer development. This sugges-
tion, however, though in agreement with previous
reports specifically addressing DNA aneuploidy as a bio-
marker of this risk [15,23], is not yet proven. On the
other hand, it is important to point out that the predic-
tive value of both dysplasia and anatomical subsite
remains in dispute [24-28]. Work is in progress to per-
form a prospective clinical study with an appropriate
cohort of patients and a long-lasting follow up to chal-
lenge the usefulness of the presently proposed
biomarker.
Conclusions
Tongue OPMLs were more frequently associated with
DNA aneuploidy and CNAs than OPMLs arising from
all the other mucosal subsites. We suggest, therefore,
that the follow-up and the management of the patients
with tongue OPMLs should receive a distinctive special
attention.
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